Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

(2015) Johannes Kraus et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The novel  2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

(2015) M. Kraus et al.   HAEMATOLOGICA

Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells

(2015) E E Fink et al.   LEUKEMIA

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy

(2015) T Narita et al.   Blood Cancer Journal

The novel  2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

(2015) M. Kraus et al.   HAEMATOLOGICA

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

(2014) M. Gambella et al.   HAEMATOLOGICA

Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity

(2013) A. Cagnetta et al.   BLOOD

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

(2013) Robert Z. Orlowski   CANCER CELL

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma

(2013) Holly A. F. Stessman et al.   PLoS One

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

(2012) E Ballabio et al.   Blood Cancer Journal

KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells

(2011) S. Mannava et al.   BLOOD

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

(2011) Y. X. Zhu et al.   BLOOD

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

(2011) S. C. W. Ling et al.   HAEMATOLOGICA

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

(2010) P. Perez-Galan et al.   BLOOD

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

(2010) M Ri et al.   LEUKEMIA

Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma

(2010) Michihide Tokuhira et al.   LEUKEMIA RESEARCH

Oxidative Folding: Cellular Strategies for Dealing with the Resultant Equimolar Production of Reactive Oxygen Species

(2009) Yuichiro Shimizu et al.   ANTIOXIDANTS & REDOX SIGNALING

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

(2008) Masaki Ri et al.   CANCER SCIENCE

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE